Recro Pharma Inc. (REPH)
NASDAQ: REPH
· Real-Time Price · USD
2.09
-0.01 (-0.48%)
At close: Mar 22, 2022, 5:00 AM
Recro Pharma Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 94.64M | 91.19M | 89.19M | 90.55M | 90.21M | 88.24M | 84.89M | 79.75M | 75.36M | 62.97M | 64.02M | 61.52M |
Cost of Revenue | 76.5M | 73.91M | 70.1M | 70.24M | 67.08M | 65.34M | 62.45M | 57.31M | 55.54M | 52.34M | 50.92M | 50.22M |
Gross Profit | 18.14M | 17.28M | 19.1M | 20.31M | 23.14M | 22.89M | 22.44M | 22.44M | 19.82M | 10.63M | 13.1M | 11.31M |
Operating Income | -3.57M | -41.98M | -40.01M | -38.74M | -32.84M | 763K | 884K | 2.42M | 412K | -7.92M | -5.78M | -8.64M |
Interest Income | 394K | 319K | 240K | 131K | n/a | n/a | n/a | n/a | n/a | -30K | -30K | -30K |
Pretax Income | -13.14M | -20.44M | -19.18M | -19.12M | -18.78M | -13.07M | -13.23M | -8.87M | -11.37M | -20.68M | -19.32M | -26.57M |
Net Income | -13.27M | -21.66M | -23.94M | -27.27M | -30.26M | -26.9M | -23.51M | -15.74M | -14.82M | -20.68M | -19.32M | -26.57M |
Selling & General & Admin | 21.02M | 21.25M | 21.02M | 20.91M | 21.95M | 21.24M | 20.77M | 19.4M | 18.37M | 17.72M | 18.18M | 19.3M |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 687K | 67.82M | 67.89M | 67.94M | 67.98M | 887K | 778K | 612K | 1.04M | 835K | 700K | 646K |
Operating Expenses | 21.71M | 89.07M | 88.91M | 88.85M | 89.94M | 22.13M | 21.55M | 20.01M | 19.41M | 18.56M | 18.88M | 19.94M |
Interest Expense | -9.96M | -31.81M | -25.35M | -19.62M | -14.06M | 13.83M | 14.11M | 14.65M | 15.13M | 16.11M | 16.9M | 17.93M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4.65M | 4.65M | 4.65M |
Cost & Expenses | 98.21M | 162.98M | 159.01M | 159.09M | 157.01M | 87.47M | 84M | 77.33M | 74.95M | 70.89M | 69.8M | 70.16M |
Income Tax Expense | 132K | 1.22M | 4.76M | 8.14M | 11.48M | 13.83M | 10.29M | 6.87M | 3.45M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 95.23M | 100.64M | 87.33M | 84.8M | 57.88M | 56.67M | 56.6M | 56.35M | 51.42M | 51.42M | 39.02M | 29.74M |
Shares Outstanding (Diluted) | 95.23M | 100.64M | 87.33M | 84.8M | 57.88M | 56.67M | 56.6M | 56.35M | 51.42M | 51.42M | 39.35M | 29.74M |
EPS (Basic) | -0.15 | -0.3 | -0.37 | -0.46 | -0.54 | -0.49 | -0.44 | -0.29 | -0.38 | -0.75 | -0.77 | -1.05 |
EPS (Diluted) | -0.15 | -0.3 | -0.37 | -0.46 | -0.54 | -0.49 | -0.44 | -0.29 | -0.38 | -0.75 | -0.77 | -1.05 |
EBITDA | -12.84M | -44.02M | -39.89M | -36.59M | -34.85M | 6.88M | 6.74M | 11.26M | 11.33M | 3.1M | 3.34M | -4.53M |
EBIT | -23.11M | -52.24M | -44.53M | -38.74M | -31.98M | 1.61M | 1.74M | 6.63M | 3.76M | -4.57M | -4.91M | -10.1M |
Depreciation & Amortization | 8.94M | -1.96M | 246.09K | 2.15M | n/a | 8.13M | 7.87M | 7.5M | 7.57M | 7.67M | 7.98M | 8.48M |